Distribution of high and low risk HPV types by cytological status: a population based study from Italy.
BACKGROUND
HPV type distribution by cytological status represents useful information to predict the impact of mass vaccination on screening programs.


METHODS
women aged from 25 to 64 who attended cervical cancer screening in five different Italian regions were tested for HPV infection with Hybrid Capture II (HCII) low and high risk probes. Women repeating Pap-test upon unsatisfactory or positive results, or as a post-treatment and post-colposcopy follow-up analysis, were excluded from our study. High risk (HR) HPV positive samples were typed using GP5+/GP6+ primed PCR, followed by Reverse Line Blot for 18 high/intermediate risk HPV types, while low risk (LR) HPV positive samples were tested with type specific primers for HPV6 and HPV11.


RESULTS
3410 women had a valid HCII and Pap-test. The prevalence of HR and LR infections was 7.0% and 3.6%, 29.1% and 13.7%, 68.1% and 31.9%, 60.0% and 0.0%, 65.0% and 12.0%, for negative, ASC-US, L-SIL, ASC-H and H-SIL cytology, respectively. The fraction of ASC-US+ cytology due to HPV 16 and 18 ranged from 11.2 (HPV 16/18 alone) to 15.4% (including HPV 16/18 in co-infection with other virus strains), and that due to HPV 6 and 11 ranged from 0.2% (HPV 6/11 alone) to 0.7% (including HPV 6/11 in co-infection with other LR virus strains).


CONCLUSIONS
mass vaccination with bivalent or quadrivalent HPV vaccine would modestly impact on prevalence of abnormal Pap-test in screening.
Laziosanità - Agency for Public Health, Lazio Region, Via di S, Costanza 53, 00198 - Rome, Italy. giorgirossi@asplazio.it.
Paolo
P
Giorgi Rossi
Francesco
F
Chini
Simonetta
S
Bisanzi
Elena
E
Burroni
Giuseppe
G
Carillo
Amedeo
A
Lattanzi
Claudio
C
Angeloni
Aurora
A
Scalisi
Rosalba
R
Macis
Maria T
MT
Pini
Paola
P
Capparucci
Gabriella
G
Guasticchi
Francesca M
FM
Carozzi
Am J Epidemiol. 1979 Aug;110(2):103-4
313702
Br J Cancer. 2010 Mar 2;102(5):933-9
20104226
Vaccine. 2008 Mar 14;26 Suppl 1:A16-23
18642468
J Natl Cancer Inst. 2006 Jun 7;98(11):765-74
16757701
J Natl Cancer Inst. 2008 Apr 2;100(7):492-501
18364502
BMC Infect Dis. 2010 Jul 20;10:214
20646310
Lancet Oncol. 2005 Apr;6(4):204
15830458
Lancet. 2005 Sep 17-23;366(9490):991-8
16168781
Am J Clin Pathol. 2005 Nov;124(5):716-21
16203283
Br J Cancer. 2003 Jul 7;89(1):101-5
12838308
J Clin Microbiol. 2002 Mar;40(3):779-87
11880393
Eur J Cancer. 2007 Feb;43(3):476-80
17223540
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2389-400
20826836
Cancer. 2008 Aug 25;114(4):242-8
18484643
Lancet. 2009 Jul 25;374(9686):301-14
19586656
Epidemiol Prev. 2009 May-Jun;33(3 Suppl 2):41-56
19776486
BMC Health Serv Res. 2006 Mar 17;6:36
16545125
J Infect Dis. 2010 Dec 15;202(12):1789-99
21067372
J Infect Dis. 2009 Apr 1;199(7):926-35
19236279
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64
15894666
Lancet Oncol. 2010 Mar;11(3):249-57
20089449
Cytopathology. 2003 Jun;14(3):115-20
12828719
Arch Med Res. 2009 Aug;40(6):478-85
19853188
Vaccine. 2008 Dec 9;26(52):6743-4
18950669
Eur J Cancer. 1997 Jul;33(8):1262-7
9301453
JAMA. 2002 Apr 24;287(16):2114-9
11966386